Integrated Bioinformatics And Experimental Validation Reveal The Role Of Jarid2 In Ovarian Cancer

Abstract

Aim: To develop novel prognostic markers for early detection and prognosis of ovarian cancer (OC). Materials & methods: We utilized bioinformatics analysis to identify and construct a prognostic model consisting of lncRNAs centered around JARID2 and explored the potential ceRNA network in OC. Cell functional experiments were conducted to validate the reliability of the ceRNA network and investigate the functional role of JARID2 in OC. Results: We constructed a nomogram composed of ten lncRNAs and identified the PKD1P6/miR-424-5p/JARID2 axis. Furthermore, our findings indicated that JARID2 promotes the proliferation of SKOV3 cells, suggesting its oncogenic role in OC. Conclusion: JARID2, potentially regulated by the PKD1P6/miR-424-5p/JARID2 axis, represents a potential novel biomarker for OC.

Plain language summary

In this study, we aimed to find new markers that can help detect and diagnose ovarian cancer (OC) at an early stage. To achieve this, we used advanced computer analysis to identify a specific gene called JARID2 and its associated lncRNAs. We also explored how these molecules interact with each other in OC cells. Through our experiments, we developed a model called a nomogram that includes ten lncRNAs. We discovered a specific pathway involving the PKD1P6 gene, a molecule called miR-424-5p and the JARID2 gene. This pathway appears to play a role in promoting the growth of OC cells. Based on our findings, JARID2, possibly regulated by the PKD1P6/miR-424-5p/JARID2 pathway, shows promise as a new biomarker for OC. This research may contribute to early detection and prognosis of the disease.

Tweetable abstract

Developing novel prognostic markers for #ovarian cancer! Bioinformatics analysis identified a JARID2-centered prognostic model with lncRNAs, revealing the PKD1P6/miR-424-5p/JARID2 axis’s role in promoting cell proliferation. Exciting potential for JARID2 as a novel biomarker!

Keywords::

• ceRNA
• JARID2
• ovarian cancer
• TCGA

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/epi-2023-0128

Conceptualization, original draft preparation, review and editing: D Huang and H Wang. Formal analysis, investigation and resources: L Tian. Major revision of the manuscript, supplementary biological function experiments and text and language polishing: R Wang. All authors have read and agreed to the final version of the manuscript.

Acknowledgments

The authors would like to thank all the researchers who contributed to The Cancer Genome Atlas database.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Data availability statement

Data used in this study can be downloaded from The Cancer Genome Atlas (https://tcga-data.nci.nih.gov/tcga/), University of California Santa Cruz Xena (https://xenabrowser.net/datapages/) and CellMiner (https://discover.nci.nih.gov/cellminer/home.do).